Source comparison
CJC-1295 DAC vs Short-Acting GHRH: Pulsatility Considerations
A critical distinction for longevity research design is the difference between CJC-1295 DAC (sustained GH elevation — blunted pulsatility) and short-acting GHRH analogues (Sermorelin: short-acting, pulsatile) or GHS-R1a agonists (Ipamorelin, GHRP-6: pulsatile)
This comparison does not assign a generated winner or score.
- A critical distinction for longevity research design is the difference between CJC-1295 DAC (sustained GH elevation — blunted pulsatility) and short-acting GHRH analogues (Sermorelin: short-acting, pulsatile) or GHS-R1a agonists (Ipamorelin, GHRP-6: pulsatile):
- Half-life
- 6–8 days
- ~11 min
- ~2 hours
- ~15 min
- GH pulse preservation
- Blunted/sustained
- Preserved
- None (tonic)
- GHRHR feedback loop
- Potentially desensitised
- N/A
- IGF-1 trajectory
- Sustained elevated
- Pulsatile elevation
- High tonic
- Weekly dosing possible
- Yes (DAC technology)
- No (daily required)
- No (daily)
- The blunted pulsatility of CJC-1295 DAC is a mechanistically relevant characteristic: physiological GH pulses drive distinct metabolic consequences (particularly hepatic IGF-1 production) compared to tonic GH. Sustained GHRHR stimulation by DAC may induce partial GHRHR downregulation over time — a counterproductive effect that must be characterised in chronic dosing studies using receptor binding assays (radioligand binding, GHRHr surface expression by flow on pituitary cells) or functional GH response after wash-out.